Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EQUATE
NCT04566328Phase 3Recruiting
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- Feb 2021
- Primary completion
- Dec 2027
- Countries
- 2
01
Overview
A Phase 3 trial of bortezomib in multiple myeloma (MM), sponsored by ECOG-ACRIN Cancer Research Group. Started Feb 2021; status: recruiting.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04566328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04566328.